Publications

Explore Meyerson laboratory research publications. Want a reprint of one of our papers? Email us!

• Primary
• Lab & Collaborative
• Review
• BioRxiv

<

>

​Primary articles are original research publications where a member of the Meyerson laboratory is either first, co-first, corresponding or co-corresponding author.

---

2025

• Pulice, Meyerson. Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. Molecular Cell. 2025 Apr 3.
• Ahmad et al. PACT prevents aberrant activation of PKR by endogenous dsRNA without sequestration. Nat Commun. 2025 Apr 8;16(1):3325.
• Ellrot et al. Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets. Cancer Cell. 2025 Feb 10.

2024

• Aquilanti et al. Velcrin molecular glues induce apoptosis in glioblastomas with high PDE3A and SLFN12 expression. Neurooncol Adv. 2024 Jul 1;6(1):vdae115. ​
• Hayes et al. Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants. Nature Communications. 2024 Mar 28
• Tan et al. Neotelomeres and telomere-spanning chromosomal arm fusions in cancer genomes revealed by long-read sequencing. Cell Genom. 2024 Jul 10;4(7):100588
• Yermalovich et al. An essential role for Cmtr2 in mammalian embryonic development. Dev Biol. 2024 Jul 31;516:47-58.
• Zou et al. XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells. Cell Reports. 2024 Jan 22

2023

• Aquilanti et al. Telomerase inhibition is an effective therapeutic strategy in TERT promoter mutant-glioblastoma models with low tumor volume. Neuro Oncol. 2023 Jan 24:noad024.
• Gibson, et al. Bifunctional Small Molecules That Induce Nuclear Localization and Targeted Transcriptional Regulation. Journal of the American Chemical Society. 2023 Nov 22; 145(48): 26028-26037
• Orsi et al. Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists. Bioorg Med Chem. 2023 Jan 15;78:117130.
• Shih J, et al. Cancer aneuploidies are shaped primarily by effects on tumour fitness. Nature. 2023 Jul;619(7971):793-800. 
• Tarantino et al. Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature Communications. 2023 Nov 18

2022

• Freeman et al. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Rep Med. 2022 Feb 15;3(2):100500.
• Gao et al. Tangent normalization for somatic copy-number inference in cancer genome analysis. Bioinformatics. 2022 Oct 14;38(20):4677-4686.
• Lee et al. Velcrin-induced selective cleavage of tRNALeu(TAA) by SLFN12 causes cancer cell death. Nat Chem Biol. 2022 Oct 27.
• Mäkinen, Zhou, Zhang et al. Whole genome sequencing reveals the independent clonal origin of multifocal ileal neuroendocrine tumors. Genome Med. 2022 Aug 3;14(1):82.
• Nomburg et al. Long-read sequencing reveals complex patterns of wraparound transcription in polyomaviruses. PLoS Pathog. 2022 Apr 1;18(4).
• Nomburg et al. An international report on bacterial communities in esophageal squamous cell carcinoma. Int J Cancer. 2022 Dec 1;151(11):1947-1959.​
• Orsi et al. Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069. J Med Chem. 2022 Oct 21.
• Tan, Slevin, Meyerson, Li. Identifying and correcting repeat-calling errors in nanopore sequencing of telomeres. Genome Biol. 2022 Aug 26;23(1):180.
• Zhang, Golomb, Meyerson. Functional genomic analysis of CDK4 and CDK6 gene dependency across human cancer cell lines. Cancer Res. 2022 Apr 8:canres.2428.2021.
• Zhou et al. Patterns of structural variation define prostate cancer across disease states. JCI Insight. 2022 Aug 9:e161370.

2021

• Carrot-Zhang et al. Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. Cell Rep. 2021 Feb 2;34(5).
• Carrot-Zhang et al. Analytical protocol to identify local ancestry-associated molecular features in cancer. STAR Protoc. 2021 Sep 20;2(4):100766.
• Garvie et al. Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase. Nature Communications. 2021 Jul 16;12(1):4375. 
• Lee & Meyerson. Antigen identification for HLA class I– and HLA class II–restricted T cell receptors using cytokine-capturing antigen-presenting cells. Science Immunology. 2021 Jan 22;6(55).
• Mäkinen, Zhou, et al. Genomic evolution in a patient with lung adenocarcinoma with a germline EGFR T790M mutation. JTO Clinical and Research Reports. 2021 Apr 1;2(4).
• Spurr et al. Quantification of aneuploidy in targeted sequencing data using ASCETS. Bioinformatics. 2021 Aug 25;37(16):2461-2463.
• Tan et al. Haplotype-resolved germline and somatic alterations in renal medullary carcinomas. Genome Med. 2021 Jul 14;13(1):114. 
• Zhou, Wu, Zhang et al. Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma. Gut. 2021 Mar 31:gutjnl-2020-323276.

2020

• Carrot-Zhang et al. Comprehensive analysis of genetic ancestry and its molecular correlates in cancer. Cancer Cell. 2020 May 11;37(5):639-654.
• Carrot-Zhang et al. Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations. Cancer Discov. 2020 Dec 2:CD-20-1165.
• Lamberti, Spurr et al. Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Ann Oncol. 2020 Apr 27. pii: S0923-7534(20)36078-6.
• Llabata et al. Multi-Omics analysis identifies MGA as a negative regulator of the MYC pathway in lung adenocarcinoma. Mol Cancer Res. 2020 Apr;18(4):574-584.
• Nomburg, Bullman et al. Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020 Mar 24;4(6):1006-1011.
• Nomburg, Meyerson, & DeCaprio. Pervasive generation of non-canonical subgenomic RNAs by SARS-CoV-2. Genome Med. 2020 Nov 9;12(108).
• Touat, Li et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 Apr;580(7804):517-523.
• Wu et al. Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. J Biol Chem. 2020 Mar 13;295(11):3431-3446.
• Zhang, Mäkinen, et al. Patterns of chromosome 18 loss of heterozygosity in multifocal ileal neuroendocrine tumors. Genes Chromosomes Cancer. 2020 Apr 14. PMID: 32291827.

2019

• Cai, Choi, Gelbard, & Meyerson. Identification and characterization of oncogenic SOS1 mutations in lung adenocarcinoma. Mol Cancer Res. 2019 Apr;17(4):1002-1012.
• Chen, Carrot-Zhang et al. Genomic and immune profiling of pre-invasive lung adenocarcinoma. Nat Commun. 2019 Nov 29;10(1):5472.
• Hayes et al. A functional landscape of resistance to MEK1/2 and CDK4/6 inhibition in NRAS-mutant melanoma. Cancer Res. 2019 05 01; 79(9):2352-2366.
• Lewis, de Waal, Wu et al. Optimization of PDE3A modulators for SLFN12-dependent cancer cell killing. ACS Med Chem Lett. 2019 Nov 14; 10(11):1537-1542.
• Stover, Baco, Cohen, Li et al. Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer. Mol Cancer Res. 2019 11; 17(11):2281-2293.

2018

• Gannon, Zou et al. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun. 2018 Dec 21;9(1):5450.
• Taylor, Shih, Ha et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell. 2018 Apr 9;33(4):676-689.e3.
• Viswanathan et al. Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet. 2018 07; 50(7):937-943.
• Viswanathan, Ha, Hoff et al. Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing. Cell. 2018 Jul 12;174(2):433-447.e19.
• Walker et al. GATK PathSeq: a customizable computational tool for the discovery and identification of microbial sequences in libraries from eukaryotic hosts. Bioinformatics. 2018 Dec 15;34(24):4287-4289.
• Zhang, Choi et al. Somatic superenhancer duplications and hotspot mutations lead to oncogenic activation of the KLF5 transcription factor. Cancer Discov. 2018 Jan;8(1):108-125.

2017

• Adalsteinsson, Ha, Freeman et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017 Nov 6;8(1):1324.
• Bullman, Pedamallu et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 2017 Dec 15;358(6369):1443-1448.
• Campbell et al. Comparison of prevalence and types of mutations in lung cancers among black and white populations. JAMA Oncol. 2017 Jun 1;3(6):801-809.
• Cherniack et al. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell. 2017 Mar 13;31(3):411-423.
• Goldstein et al. Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer. Cancer Res. 2017 Sep 18. pii: canres.1701.2017.
• Imielinski, Guo and Meyerson. Insertions and deletions target lineage-defining genes in human cancers. ​Cell. 2017 Jan 26;168(3):460-472.e14.
• Lu et al. MET Exon 14 mutation encodes an actionable therapeutic target in lung adenocarcinoma. Cancer Res. 2017 Aug 15;77(16):4498-4505.
• Robertson, Shih, Yau et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017 Aug 14;32(2):204-220.e15.​

2016

• Berger, Brooks, Wu et al. High-throughput phenotyping of lung cancer somatic mutations. Cancer Cell. 2016 Aug 8;30(2):214-228.
• Beroukhim, Zhang and Meyerson. Copy number alterations unmasked as enhancer hijackers. ​Nat Genet. 2016 Dec 28;49(1):5-6.​
• Campbell et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016 Jun;48(6):607-16.​​
• Gannon et al. Identification of an "exceptional responder" cell line to MEK1 inhibition: Clcnical implications for MEK-targeted therapy. Mol Cancer Res. 2016 Feb;14(2):207-15.
• Lin, Francis et al. Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets. Cancer Biol Ther. 2016 Dec;17(12):1274-1281.
• Pedamallu, Bhatt, Bullman et al. Metagenomic Characterization of microbial communities In Situ within the deeper layers of the ileum in Crohn's disease. Cell Mol Gastroenterol Hepatol. 2016 May 26;2(5):563-566.e5.
• Shankar et al. BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology. Acta Neuropathol. 2016 Jan;131(1):147-50.​
• de Waal et al. Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nat Chem Biol. 2016 Feb;12(2):102-8.
• Zhang et al. Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat Genet. 2016 Feb;48(2):176-82.

2015

• Arvey et al. The tumor virus landscape of AIDS-related lymphomas. Blood. 2015 May 14;125(20):e14-22.
• Bambury et al. DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC Cancer. 2015 Apr 9;15:242.
• Berrios et al. Malawi polyomavirus is a prevalent human virus that interacts with known tumor suppressors. J Virol. 2015 Jan;89(1):857-62.
• Guo et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015 Jan 15;75(2):264-9.
• Lin et al. Dynamic epigenetic regulation by menin during pancreatic islet tumor formation. Mol Cancer Res. 2015 Apr;13(4):689-98.
• Ramos et al. Oncotator: cancer variant annotation tool. Hum Mutat. 2015 Apr;36(4):E2423-9.
• Shankar, Francis et al. Rapid intraoperative molecular characterization of glioma. JAMA Oncol. 2015 Aug;1(5):662-7.
• van de Wetering et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015 May 7;161(4):933-45.
• Zhang et al. Calibrating genomic and allelic coverage bias in single-cell sequencing. Nat Commun. 2015 Apr 16;6:6822.
• Zhang et al. Chromothripsis from DNA damage in micronuclei. Nature. 2015 June 11;522(7555):179-84.

2014

• Berger, Imielinski et al. Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene. 2014 Aug 28;33(35):4418-23.
• Bhatt et al. In search of a candidate pathogen for giant cell arteritis: Sequencing based characterization of the giant cell arteritis microbiome. Arthritis Rheumatol. 2014 Jul;66(7):1939-44.
• Brooks et al. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS One. 2014 Jan 31;9(1):e87361.
• Cancer Genome Atlas Research Network (M. Meyerson, corresponding author). Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014 Jul 31;511(7511):543-50.
• Cho, Bass et al. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer. 2014 Jun 4;13(1):141.
• Choi & Meyerson. Targeted genomic rearrangements using CRISPR/Cas technology. Nat Commun. 2014 Apr 24;5:3728.
• Francis, Zhang et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014 Aug;4(8):956-71.
• Helman et al. Somatic retrotransposition in human cancer revealed by whole-genome and exome sequencing. Genome Res. 2014 Jul;24(7):1053-63.
• Hoadley et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014 Aug 14;158(4):929-44.
• Imielinski, Greulich, Kaplan et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014 Apr 1;124(4):1582-6.
• Kim, Hammerman et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. 2014 Jan 10;32(2):121-8.
• Ojesina et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014 Feb 20;506(7488):371-5.
• Parfenov, Pedamallu et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15544-9.
• Pugh et al. Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences. Oncogene. 2014 Nov 6;33(45):5295-302.
• Sharifnia et al. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18661-6. doi: 10.1073/pnas.1412228112.
• TCGA. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385.
• Watanabe et al. SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. J Clin Invest. 2014 Apr 1;124(4):1636-45.

2013

• Abazeed et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 2013 Oct 15;73(20):6289-98.
• Bhatt, Freeman et al. Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. New Engl J Med. 2013 Aug 8;369(6):517-28.
• Chmielecki et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013 Feb;45(2):131-2.
• Cho et al. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res. 2013 Nov 15;73(22):6770-9.
• Francis et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013 Dec;45(12):1483-6.
• Kostic et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013 Aug 14;14(2):207-15.
• Liao et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013 Aug 15;73(16):5195-205.
• Pugh et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013 Mar;45(3):279-84.
• Verhaak et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013 Jan 2;123(1):517-25.
• Watanabe, Francis et al. Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev. 2013 Jan 15;27(2):197-210. 
• Zack et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013 Sep 26;45(10):1134-40.

2012

• Banerji et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012 Jun 20;486(7403):405-9.
• Cancer Genome Atlas Research Network (M. Meyerson, corresponding author). Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27;489(7417):519-25.    
• Carter et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012 May;30(5):413-21.
• Greulich et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81.
• Imielinski et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012 Sep 14;150(6):1107-20.
• Kostic et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012 Feb;22(2):292-8. doi: 10.1101/gr.126573.111.
• Pugh et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012 Aug 2;488(7409):106-10.
• TCGA. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27;489(7417):519-25. doi: 10.1038/nature11404.

2011

• Bass et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011 Sep 4;43(10):964-8.
• Cho et al. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res. 2011 Dec 15;71(24):7587-96.
• Dutt et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 2011;6(6):e20351.
• Francis et al. The menin tumor suppressor protein is phosphorylated in response to DNA damage. PLoS One. 2011 Jan 14;6(1):e16119.
• Hammerman et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Jun;1(1):78-89.
• Kostic et al. PathSeq: software to identify or discover microbes by deep sequencing of human tissue. Nat Biotechnol. 2011 May;29(5):393-6.
• Lin et al. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13379-86.
• Mermel et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.

2010

• Barretina et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010 Aug;42(8):715-21.     
• Beroukhim et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18;463(7283):899-905.
• Verhaak et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 Jan 19;17(1):98-110.

2009

• Bass et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009 Nov;41(11):1238-42.     
• Beroukhim et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009 Jun 1;69(11):4674-81.​
• Chiang et al. High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods. 2009 Jan;6(1):99-103.
• Ramos et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther. 2009 Nov;8(21):2042-50.
• Rozenblatt-Rosen et al. The tumor suppressor Cdc73 functionally associates with CPSF and CstF 3' mRNA processing factors. Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):755-60.

2008

• Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008 Oct 23;455(7216):1061-8.
• Chiang et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 2008 Aug 15;68(16):6779-88.
• Ding et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008 Oct 23;455(7216):1069-75.​
• Dutt et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8713-7.
• George et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008 Oct 16;455(7215):975-8.
• Li et al. Major copy proportion analysis of tumor samples using SNP arrays. BMC Bioinformatics. 2008 Apr 21;9:204.

2007

• Minami et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene. 2007 Jul 26;26(34):5023-7.
• Thomas et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar;39(3):347-51.
• Weir et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Dec 6;450(7171):893-8.
• Yuza et al. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther. 2007 May;6(5):661-7.

2006

• Hayes et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol. 2006 Nov 1;24(31):5079-90.
• Ji et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A. 2006 May 16;103(20):7817-22.
• Lee et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec;3(12):e485.
• MacConaill et al. Phosphorylation of the menin tumor suppressor protein on serine 543 and serine 583. Mol Cancer Res. 2006 Oct;4(10):793-801.
• Thomas et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med. 2006 Jul;12(7):852-5.

2005

• Greulich et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov;2(11):e313.​
• LaFramboise et al. Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput Biol. 2005 Nov;1(6):e65.
• Rozenblatt-Rosen et al. The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol. 2005 Jan;25(2):612-20.
• Thomas et al. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. Cold Spring Harb Symp Quant Biol. 2005;70:73-81.
• Zhao et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 2005 Jul 1;65(13):5561-70.

2004

• Hughes et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell. 2004 Feb 27;13(4):587-97.
• Jänne et al. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene. 2004 Apr 8;23(15):2716-26.
• Paez et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 4;304(5676):1497-500.
• Scacheri et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1892-7.
• Tengs et al. Genomic representations using concatenates of Type IIB restriction endonuclease digestion fragments. Nucleic Acids Res. 2004 Aug 25;32(15):e121.
• Zhao et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res. 2004 May 1;64(9):3060-71.

2000-2003

• Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5.
• Lindblad-Toh K, Tanenbaum DM, Daly MJ, Winchester E, Lui WO, Villapakkam A, Stanton SE, Larsson C, Hudson TJ, Johnson BE, Lander ES, Meyerson M. Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nat Biotechnol. 2000 Sep;18(9):1001-5.
• Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 2002 Dec 1;62(23):7001-3.
• Stanton SE, Shin SW, Johnson BE, Meyerson M. Recurrent allelic deletions of chromosome arms 15q and 16q in human small cell lung carcinomas. Genes Chromosomes Cancer. 2000 Mar;27(3):323-31.
• Weber G, Shendure J, Tanenbaum DM, Church GM, Meyerson M. Identification of foreign gene sequences by transcript filtering against the human genome. Nat Genet. 2002 Feb;30(2):141-2.
• Xu Y, Stange-Thomann N, Weber G, Bo R, Dodge S, David RG, Foley K, Beheshti J, Harris NL, Birren B, Lander ES, Meyerson M. Pathogen discovery from human tissue by sequence-based computational subtraction. Genomics. 2003 Mar;81(3):329-35.

Pre-2000

• Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, Weinberg RA. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene. 1998 Mar 5;16(9):1217-22.
• Counter CM, Meyerson M, Eaton EN, Weinberg RA. The catalytic subunit of yeast telomerase. Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9202-7.
• Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JH, Meyerson M, Weinberg RA. Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999 Oct;5(10):1164-70.
• Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA, Gerald WL. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet. 1998 Jun;19(2):182-6.
• Meyerson M, Enders GH, Wu CL, Su LK, Gorka C, Nelson C, Harlow E, Tsai LH. A family of human cdc2-related protein kinases. EMBO J. 1992 Aug;11(8):2909-17.
• Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997 Aug 22;90(4):785-95.
• Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol. 1994 Mar;14(3):2077-86.
• Meyerson M, Faha B, Su LK, Harlow E, Tsai LH. The cyclin-dependent kinase family. Cold Spring Harb Symp Quant Biol. 1991;56:177-86.
• Meyerson M. Telomerase enzyme activation and human cell immortalization. Toxicol Lett. 1998 Dec 28;102-103:41-5.
• Tsai LH, Harlow E, Meyerson M. Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase. Nature. 1991 Sep12;353(6340):174-7.

Lab & collaborative articles are Meyerson laboratory publications, as well as publications led by other groups, where a member or members of the Meyerson Laboratory shares authorship.

---

2024

• Resolution of ring chromosomes, Robertsonian translocations, and complex structural variants from long-read sequencing and telomere-to-telomere assembly. Am J Hum Genet. 2024 Dec 5;111(12):2693-2706.​
• Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo-Active KAT6AB Inhibitor. J Med Chem. 2024 Nov 14; 14;67(21
• ):19282-19303.
• Discovery of BAY 2666605, a Molecular Glue for PDE3A and SLFN12. ACS Medicinal Chemistry Letters. 2024 Sep 10. 10; 15(1):1662-1667.
• Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun . 2024 Jul 11;15(1):5837.
• Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants. Nat Commun. 2024 Mar 28; 15(1):2742. 
• XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells. Cell Rep. 2024 Feb 27; 43(2):113783.

2023

• Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker. Cancer Discov. 2023 12 12; 13(12):2532-2547. ​
• Neotelomeres and Telomere-Spanning Chromosomal Arm Fusions in Cancer Genomes Revealed by Long-Read Sequencing. bioRxiv. 2023 Dec 01. 
• Bifunctional Small Molecules That Induce Nuclear Localization and Targeted Transcriptional Regulation. J Am Chem Soc. 2023 12 06; 145(48):26028-26037. 
• Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nat Commun. 2023 11 18; 14(1):7496. 
• Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Clin Cancer Res. 2023 11 14; 29(22):4627-4643. 
• Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer. J Clin Invest. 2023 11 01; 133(21). 
• Dosage amplification dictates oncogenic regulation by the NKX2-1 lineage factor in lung adenocarcinoma. bioRxiv. 2023 Oct 27. 
• Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors. Pediatr Blood Cancer. 2023 11; 70(11):e30643. 
• XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells. bioRxiv. 2023 Aug 03. 
• Bifunctional small molecules that induce nuclear localization and targeted transcriptional regulation. bioRxiv. 2023 Jul 07. 
• Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume. Neuro Oncol. 2023 07 06; 25(7):1275-1285. 
• Cancer aneuploidies are shaped primarily by effects on tumour fitness. Nature. 2023 Jul; 619(7971):793-800. 
• Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC. J Thorac Oncol. 2023 11; 18(11):1524-1537. 
• Molecular portraits of lung cancer evolution. Nature. 2023 04; 616(7957):435-436. 
• Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker. bioRxiv. 2023 Mar 17. 
• Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists. Bioorg Med Chem. 2023 01 15; 78:117130. 
• Velcrin-induced selective cleavage of tRNALeu(TAA) by SLFN12 causes cancer cell death. Nat Chem Biol. 2023 03; 19(3):301-310.

2022

• Discovery and Structure-Based Design of Potent Covalent PPAR? Inverse-Agonists BAY-4931 and BAY-0069. J Med Chem. 2022 11 10; 65(21):14843-14863. ​
• Fusobacterium and Colorectal Cancer: Important Association or Random Coincidence? Cancer Res. 2022 10 17; 82(20):3671-3672. 
• Tangent normalization for somatic copy-number inference in cancer genome analysis. Bioinformatics. 2022 10 14; 38(20):4677-4686. 
• Patterns of structural variation define prostate cancer across disease states. JCI Insight. 2022 09 08; 7(17). 
• Identifying and correcting repeat-calling errors in nanopore sequencing of telomeres. Genome Biol. 2022 08 26; 23(1):180. 
• An international report on bacterial communities in esophageal squamous cell carcinoma. Int J Cancer. 2022 Dec 01; 151(11):1947-1959. 
• Whole genome sequencing reveals the independent clonal origin of multifocal ileal neuroendocrine tumors. Genome Med. 2022 08 03; 14(1):82. 
• Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann Oncol. 2022 10; 33(10):1029-1040. 
• Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines. Cancer Res. 2022 06 06; 82(11):2171-2184. 
• Long-read sequencing reveals complex patterns of wraparound transcription in polyomaviruses. PLoS Pathog. 2022 04; 18(4):e1010401. 
• Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Rep Med. 2022 02 15; 3(2):100500.

2021

• Telomerase as a therapeutic target in glioblastoma. Neuro Oncol. 2021 12 01; 23(12):2004-2013. ​
• Quantification of aneuploidy in targeted sequencing data using ASCETS. Bioinformatics. 2021 08 25; 37(16):2461-2463. 
• Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase. Nat Commun. 2021 07 16; 12(1):4375. 
• Haplotype-resolved germline and somatic alterations in renal medullary carcinomas. Genome Med. 2021 07 14; 13(1):114. 
• Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. Nat Genet. 2021 06; 53(6):881-894. 
• FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 10; 11(10):2488-2505. 
• Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma. Gut. 2022 04; 71(4):665-675. 
• Characterization of Plasmacytoid Dendritic Cells, Microbial Sequences, and Identification of a Candidate Public T-Cell Clone in Kikuchi-Fujimoto Disease. Pediatr Dev Pathol. 2021 May-Jun; 24(3):193-205. 
• Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. Cell Rep. 2021 02 02; 34(5):108707. 
• Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation. JTO Clin Res Rep. 2021 Apr; 2(4):100146. 
• Antigen identification for HLA class I- and HLA class II-restricted T cell receptors using cytokine-capturing antigen-presenting cells. Sci Immunol. 2021 01 22; 6(55). 
• Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clin Cancer Res. 2021 03 15; 27(6):1695-1705. 
• Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations. Cancer Discov. 2021 03; 11(3):591-598.

2020

• Pervasive generation of non-canonical subgenomic RNAs by SARS-CoV-2. Genome Med. 2020 12 01; 12(1):108. ​
• Bacterial invaders drive CRC progression. Sci Signal. 2020 08 11; 13(644). 
• Genomic Profiling of Prostate Cancers from Men with African and European Ancestry. Clin Cancer Res. 2020 09 01; 26(17):4651-4660. 
• Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann Oncol. 2020 10; 31(10):1366-1375. 
• Patterns of chromosome 18 loss of heterozygosity in multifocal ileal neuroendocrine tumors. Genes Chromosomes Cancer. 2020 09; 59(9):535-539. 
• Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Ann Oncol. 2020 06; 31(6):807-814. 
• Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020 03 24; 4(6):1006-1011. 
• Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2556-2564. 
• Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature. 2020 04; 580(7802):269-273. 
• Genomic basis for RNA alterations in cancer. Nature. 2020 02; 578(7793):129-136. 
• Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. J Biol Chem. 2020 03 13; 295(11):3431-3446. 
• Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer. 2020 02; 1(2):235-248. 
• Multi-Omics Analysis Identifies MGA as a Negative Regulator of the MYC Pathway in Lung Adenocarcinoma. Mol Cancer Res. 2020 04; 18(4):574-584.

2019

• Genomic and immune profiling of pre-invasive lung adenocarcinoma. Nat Commun. 2019 11 29; 10(1):5472. ​
• Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing. ACS Med Chem Lett. 2019 Nov 14; 10(11):1537-1542. 
• Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun. 2019 09 05; 10(1):3991. 
• Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. Mol Cancer Res. 2019 11; 17(11):2281-2293. 
• Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer. Cancer Res. 2019 03 15; 79(6):1038-1040. 
• A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma. Cancer Res. 2019 05 01; 79(9):2352-2366. 
• Commensal Microbiota Promote Lung Cancer Development via ?d T Cells. Cell. 2019 02 21; 176(5):998-1013.e16. 
• Identification and Characterization of Oncogenic SOS1 Mutations in Lung Adenocarcinoma. Mol Cancer Res. 2019 04; 17(4):1002-1012. 
• Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun. 2018 12 21; 9(1):5450. 
• GATK PathSeq: a customizable computational tool for the discovery and identification of microbial sequences in libraries from eukaryotic hosts. Bioinformatics. 2018 12 15; 34(24):4287-4289. 
• Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018 11 02; 3(21). 
• Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19). 
• The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. Am J Pathol. 2018 12; 188(12):2839-2852. 
• Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status. Cancer Immunol Res. 2018 11; 6(11):1327-1336. 
• Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018 10; 50(10):1381-1387. 
• Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2018 08 09; 174(4):1033. 
• Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018 08; 560(7718):325-330. 
• Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8388-E8394. 
• Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. JCO Precis Oncol. 2018; 2018. 
• Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019 01; 21(1):213-223.

2018

• Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet. 2018 07; 50(7):937-943. ​
• Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. 2018 07 12; 174(2):433-447.e19. 
• Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 05; 24(5):679-690. 
• RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade. Mol Cancer Ther. 2018 07; 17(7):1526-1539. 
• Mechanistic Insights into Transmissible Cancers of Mammals. Cancer Cell. 2018 04 09; 33(4):543-544. 
• Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018 04 05; 173(2):321-337.e10. 
• Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. 2018 04 09; 33(4):676-689.e3. 
• Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018 08; 32(8):1838-1841. 
• Landscapes of childhood tumours. Nature. 2018 03 15; 555(7696):316-317. 
• SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 2018 04; 28(4):581-591. 
• Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420. 
• Autophosphorylation of the carboxyl-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants. Int J Cancer. 2018 08 01; 143(3):679-685. 
• Landscapes of childhood tumours. Nature. 2018 Mar; 555(7696):316-317. 
• Unique, dual-indexed sequencing adapters with UMIs effectively eliminate index cross-talk and significantly improve sensitivity of massively parallel sequencing. BMC Genomics. 2018 01 08; 19(1):30.

2017

• High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell. 2017 12 11; 32(6):884. 
• Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017 12 15; 358(6369):1443-1448. 
• Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017 11 06; 8(1):1324. 
• Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. Cancer Discov. 2018 01; 8(1):59-73. 
• Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017 Oct 19; 171(3):540-556.e25. 
• Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. Cancer Discov. 2018 01; 8(1):108-125. 
• Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer. Cancer Res. 2017 12 15; 77(24):6987-6998. 
• Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2017 06 30; 7:46873. 
• Recurrent and functional regulatory mutations in breast cancer. Nature. 2017 07 06; 547(7661):55-60. 
• Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations. JAMA Oncol. 2017 Jun 01; 3(6):801-809. 
• MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma. Cancer Res. 2017 08 15; 77(16):4498-4505. 
• Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545. 
• Insertions and Deletions Target Lineage-Defining Genes in Human Cancers. Cell. 2017 01 26; 168(3):460-472.e14.

2016

• Copy number alterations unmasked as enhancer hijackers. Nat Genet. 2016 12 28; 49(1):5-6. ​
• Emerging Concepts and Technologies for the Discovery of Microorganisms Involved in Human Disease. Annu Rev Pathol. 2017 Jan 24; 12:217-244. 
• Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062. 
• Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location. Clin Transl Gastroenterol. 2016 Nov 03; 7(11):e200. 
• Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med. 2016 11 02; 8(363):363ra147. 
• Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets. Cancer Biol Ther. 2016 12; 17(12):1274-1281. 
• Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell. 2016 08 08; 30(2):363. 
• Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. PLoS Genet. 2016 08; 12(8):e1006242. 
• High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell. 2016 08 08; 30(2):214-228. 
• Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2016 06 24; 6:27960. 
• Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016 Aug; 6(8):914-29. 
• Metagenomic Characterization of Microbial Communities In Situ Within the Deeper Layers of the Ileum in Crohn's Disease. Cell Mol Gastroenterol Hepatol. 2016 Sep; 2(5):563-566.e5. 
• Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2016 05 10; 6:25521. 
• Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016 06; 48(6):607-16. 
• Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell. 2016 05 09; 29(5):723-736. 
• VariantBam: filtering and profiling of next-generational sequencing data using region-specific rules. Bioinformatics. 2016 07 01; 32(13):2029-31. 
• Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016 Jan 28; 164(3):550-63. 
• BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology. Acta Neuropathol. 2016 Jan; 131(1):147-50. 
• Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat Genet. 2016 Feb; 48(2):176-82. 
• Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nat Chem Biol. 2016 Feb; 12(2):102-8. 
• Identification of an Exceptional Responder Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Mol Cancer Res. 2016 Feb; 14(2):207-15. 
• Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016 Jan 14; 374(2):135-45.

2015

• Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the ?-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Cold Spring Harb Mol Case Stud. 2015 Oct; 1(1):a000539. 
• Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177. 
• Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. ACS Chem Biol. 2015 Dec 18; 10(12):2687-96. 
• Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016 12; 65(12):1973-1980. 
• Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Nat Struct Mol Biol. 2015 Sep; 22(9):703-711. 
• Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7. 
• NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. Mol Cancer Ther. 2015 Oct; 14(10):2382-2389. 
• Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer. 2015 Oct; 54(10):606-15. 
• Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor. Clin Cancer Res. 2016 Jan 01; 22(1):250-8. 
• Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015 Jun 25; 372(26):2481-98. 
• Chromothripsis from DNA damage in micronuclei. Nature. 2015 Jun 11; 522(7555):179-84. 
• Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015 May 07; 161(4):933-45. 
• Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). J Thorac Oncol. 2015 May; 10(5):838-843. 
• Calibrating genomic and allelic coverage bias in single-cell sequencing. Nat Commun. 2015 Apr 16; 6:6822. 
• Pugh et al. reply. Nature. 2015 Apr 16; 520(7547):E12-4. 
• DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC Cancer. 2015 Apr 09; 15:242. 
• The tumor virus landscape of AIDS-related lymphomas. Blood. 2015 May 14; 125(20):e14-22. 
• Oncotator: cancer variant annotation tool. Hum Mutat. 2015 Apr; 36(4):E2423-9. 
• A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 2015 Mar 09; 27(3):397-408. 
• Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. Int J Cancer. 2015 Aug 15; 137(4):776-83. 
• Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015 Mar; 25(3):316-27. 
• Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathol Commun. 2014 Dec 24; 2:167. 
• Dynamic epigenetic regulation by menin during pancreatic islet tumor formation. Mol Cancer Res. 2015 Apr; 13(4):689-98.

2014

• Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2014 Dec 30; 111(52):18661-6. 
• Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015 Jan 15; 75(2):264-9. 
• BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res. 2015 Feb 18; 43(3):e19. 
• Malawi polyomavirus is a prevalent human virus that interacts with known tumor suppressors. J Virol. 2015 Jan; 89(1):857-62. 
• Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014 Oct 28; 111(43):15544-9. 
• Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. Head Neck. 2015 Nov; 37(11):1642-9. 
• The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014 Sep 08; 26(3):319-330. 
• Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. Cancer Res. 2014 Sep 01; 74(17):4676-84. 
• Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecol Oncol. 2014 Sep; 134(3):599-606. 
• The p53 pathway and ancestral progenitors are associated with tumor recurrence in glioblastoma. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii3. 
• In search of a candidate pathogen for giant cell arteritis: sequencing-based characterization of the giant cell arteritis microbiome. Arthritis Rheumatol. 2014 Jul; 66(7):1939-44. 
• Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences. Oncogene. 2014 Nov 06; 33(45):5295-302. 
• Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer. 2014 Jun 04; 13:141. 
• EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014 Aug; 4(8):956-71. 
• Somatic retrotransposition in human cancer revealed by whole-genome and exome sequencing. Genome Res. 2014 Jul; 24(7):1053-63. 
• Breaking down RET breakpoints in lung adenocarcinoma. J Thorac Oncol. 2014 May; 9(5):590-2. 
• Targeted genomic rearrangements using CRISPR/Cas technology. Nat Commun. 2014 Apr 24; 5:3728. 
• Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May; 32(5):479-84. 
• SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. J Clin Invest. 2014 Apr; 124(4):1636-45. 
• A121: in search of infectious triggers of periodic Fever, aphthous stomatitis, pharyngitis and adenitis syndrome. Arthritis Rheumatol. 2014 Mar; 66 Suppl 11:S158. 
• Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014 Apr; 124(4):1582-6. 
• A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS One. 2014; 9(1):e87361. 
• Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene. 2014 Aug 28; 33(35):4418-23. 
• Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014 Feb; 4(2):216-31. 
• Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014 Jan 23; 505(7484):495-501. 
• Landscape of genomic alterations in cervical carcinomas. Nature. 2014 Feb 20; 506(7488):371-5. 
• Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013 Dec 18; 5(216):216ra177. 
• Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. 2014 Jan 10; 32(2):121-8. 
• Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Mol Cancer Ther. 2014 Feb; 13(2):475-82. 
• DNA sequencing of cancer: what have we learned? Annu Rev Med. 2014; 65:63-79. 
• Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl. 2014 Jan 03; 53(1):199-204.

2013

• Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med. 2013 11 07; 369(19):1867. 
• Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013 Dec; 45(12):1483-6. 
• The somatic genomic landscape of glioblastoma. Cell. 2013 Oct 10; 155(2):462-77. 
• Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013 Oct; 45(10):1134-40. 
• The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013 Oct; 45(10):1113-20. 
• Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013 Dec; 3(12):1355-63. 
• Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res. 2013 Nov 15; 73(22):6770-9. 
• Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One. 2013; 8(9):e74950. 
• Microbes and inflammation in colorectal cancer. Cancer Immunol Res. 2013 Sep; 1(3):150-7. 
• Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 2013 Oct 15; 73(20):6289-98. 
• Signatures of mutational processes in human cancer. Nature. 2013 Aug 22; 500(7463):415-21. 
• Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013 Aug 14; 14(2):207-15. 
• Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med. 2013 Aug 08; 369(6):517-28. 
• Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. Blood. 2013 Sep 19; 122(12):2039-46. 
• Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 04; 499(7456):43-9. 
• Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013 Aug 15; 73(16):5195-205. 
• Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11; 499(7457):214-218. 
• Hopping between differentiation states in lung adenocarcinoma. Cancer Cell. 2013 Jun 10; 23(6):707-9. 
• A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science. 2013 May 31; 340(6136):1100-6. 
• Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 02; 497(7447):67-73. 
• Punctuated evolution of prostate cancer genomes. Cell. 2013 Apr 25; 153(3):666-77. 
• Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell. 2013 Apr 25; 50(2):185-99. 
• Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013 Feb 14; 152(4):714-26. 
• Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013 Mar; 31(3):213-9. 
• The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013 Mar; 45(3):279-84. 
• Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev. 2013 Jan 15; 27(2):197-210. 
• Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013 Feb; 45(2):131-2. 
• Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013 Jan; 123(1):517-25. 
• Targeted therapy for squamous cell lung cancer. Lung Cancer Manag. 2012 Dec; 1(4):293-300. 
• Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res. 2013 Feb; 23(2):228-35.

2012

• Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012 Sep 14; 150(6):1107-20. 
• Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27; 489(7417):519-25. 
• Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012 Oct; 44(10):1104-10. 
• Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012 Sep 04; 109(36):14476-81. 
• Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012 Aug 02; 488(7409):100-5. 
• Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012 Aug 02; 488(7409):106-10. 
• Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012 Aug 02; 488(7409):49-56. 
• A landscape of driver mutations in melanoma. Cell. 2012 Jul 20; 150(2):251-63. 
• Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res. 2012 Sep 15; 18(18):4973-85. 
• Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 2012 Sep 01; 72(17):4383-93. 
• Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012 Jun 20; 486(7403):405-9. 
• Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science. 2012 Jul 06; 337(6090):104-9. 
• Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012 May 20; 44(6):685-9. 
• Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012 May 09; 485(7399):502-6. 
• Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012 May; 30(5):413-21. 
• The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012 Mar 28; 483(7391):603-7. 
• Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma. Proc Natl Acad Sci U S A. 2012 Mar 13; 109(11):4251-6. 
• Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer. 2012 Jul; 77(1):31-7. 
• ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma. J Clin Oncol. 2012 Mar 10; 30(8):878-9.

2011

• SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29; 365(26):2497-506. ​
• High order chromatin architecture shapes the landscape of chromosomal alterations in cancer. Nat Biotechnol. 2011 Nov 20; 29(12):1109-13. 
• High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012 Jan; 2(1):82-93. 
• Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012 Feb; 22(2):292-8. 
• Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011 Dec; 1(7):608-25. 
• Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res. 2011 Dec 15; 71(24):7587-96. 
• Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011 Sep 04; 43(10):964-968. 
• Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov. 2011 Sep; 1(4):297-311. 
• Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 2011 Jul 31; 43(9):869-74. 
• The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26; 333(6046):1157-60. 
• Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci U S A. 2011 Aug 16; 108(33):13379-86. 
• Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev. 2011 Jul 15; 25(14):1470-5. 
• Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A. 2011 Jul 26; 108(30):12372-7. 
• SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. Mol Cell. 2011 Jul 08; 43(1):45-56. 
• Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 2011; 6(6):e20351. 
• Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Jun; 1(1):78-89. 
• Tumor genomic profiling of FFPE samples by massively parallel sequencing. J Clin Oncol. 2011 May 20; 29(15_suppl):10502. 
• PathSeq: software to identify or discover microbes by deep sequencing of human tissue. Nat Biotechnol. 2011 May; 29(5):393-6. 
• GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. 
• Suppression of lung adenocarcinoma progression by Nkx2-1. Nature. 2011 May 05; 473(7345):101-4. 
• SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol. 2011 Jul; 24(7):944-53. 
• Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72. 
• Making sense of cancer genomic data. Genes Dev. 2011 Mar 15; 25(6):534-55. 
• Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011 Aug 01; 29(22):3085-96. 
• Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol. 2011 Apr 10; 29(11):1415-23. 
• Transcriptional activators enhance polyadenylation of mRNA precursors. Mol Cell. 2011 Feb 18; 41(4):409-18. 
• The genomic complexity of primary human prostate cancer. Nature. 2011 Feb 10; 470(7333):214-20. 
• The menin tumor suppressor protein is phosphorylated in response to DNA damage. PLoS One. 2011 Jan 14; 6(1):e16119. 
• Cancer genomes evolve by pulverizing single chromosomes. Cell. 2011 Jan 07; 144(1):9-10. 
• Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011 Apr 10; 29(11):1424-30.

2010

• A novel totivirus and piscine reovirus (PRV) in Atlantic salmon (Salmo salar) with cardiomyopathy syndrome (CMS). Virol J. 2010 Nov 10; 7:309. ​
• Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010 Oct; 11(10):685-96. 
• Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol. 2010 Oct 10; 28(29):4417-24. 
• Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010 Aug; 42(8):715-21. 
• Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010 Sep 16; 116(11):1919-23. 
• ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol. 2010 Aug; 23(8):1061-7. 
• A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol. 2010 Mar 26; 17(3):285-95. 
• An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010 Mar 16; 17(3):298-310. 
• Integrative analysis of the melanoma transcriptome. Genome Res. 2010 Apr; 20(4):413-27. 
• The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905. 
• Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 Jan 19; 17(1):98-110. 
• TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene. 2010 Mar 18; 29(11):1588-97.

2009

• Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009 Nov 18; 4(11):e7887. ​
• Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther. 2009 Nov; 8(21):2042-50. 
• Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009 Nov 05; 462(7269):108-12. 
• SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009 Nov; 41(11):1238-42. 
• In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma. Am J Clin Pathol. 2009 Oct; 132(4):500-5. 
• Genome-wide association study in esophageal squamous cell carcinoma. Gastroenterology. 2009 Nov; 137(5):1573-6. 
• Somatic mutations are present in all members of the AKT family in endometrial carcinoma. Br J Cancer. 2009 Oct 06; 101(7):1218-9; author reply 1220-1. 
• Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2009 Aug; 13(8B):1977-1986. 
• Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009 Jun 01; 69(11):4674-81. 
• Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009 Jul; 41(7):843-8. 
• Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest. 2009 Jun; 119(6):1727-40. 
• PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009 Apr 15; 69(8):3256-61. 
• Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer. 2009 Apr; 48(4):366-80. 
• Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A. 2009 Mar 24; 106(12):4834-9. 
• Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res. 2009 Feb 15; 15(4):1417-27. 
• The tumor suppressor Cdc73 functionally associates with CPSF and CstF 3' mRNA processing factors. Proc Natl Acad Sci U S A. 2009 Jan 20; 106(3):755-60. 
• HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A. 2009 Jan 13; 106(2):474-9. 
• TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol. 2009 Jan; 217(1):65-72. 
• Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20380-5. 
• High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods. 2009 Jan; 6(1):99-103.

2008

• Chromosomal deletions and progression of premalignant lesions: less is more. Cancer Prev Res (Phila). 2008 Nov; 1(6):404-8. 
• Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008 Oct 23; 455(7216):1069-75. 
• Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008 Oct 16; 455(7215):975-8. 
• CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008 Sep 25; 455(7212):547-51. 
• Functional copy-number alterations in cancer. PLoS One. 2008 Sep 11; 3(9):e3179. 
• Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008 Dec; 135(6):1972-83, 1983.e1-11. 
• Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 2008 Aug 15; 68(16):6779-88. 
• Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008 Aug; 14(8):822-7. 
• Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008 Jul 15; 68(14):5827-38. 
• EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008 Jul 01; 14(13):4275-83. 
• Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer. 2008 Jul 22; 99(2):245-52. 
• Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008 Jun 24; 105(25):8713-7. 
• A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients. J Clin Oncol. 2008 May 20; 26(15_suppl):7510. 
• Major copy proportion analysis of tumor samples using SNP arrays. BMC Bioinformatics. 2008 Apr 21; 9:204. 
• BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008 Aug 07; 27(34):4702-11. 
• Adding pathogens by genomic subtraction. Nat Genet. 2008 Apr; 40(4):380-2. 
• The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008 Apr 01; 22(7):884-93. 
• SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. Genes Chromosomes Cancer. 2008 Mar; 47(3):253-9. 
• The T790M mutatation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad SCi USA. 2008; 105(6):2070-5. 
• High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 2008 May 01; 111(9):4788-96. 
• Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008 Feb 01; 68(3):664-73. 
• HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol. 2008 Feb; 32(2):307-16. 
• The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008 Feb 12; 105(6):2070-5.

2007

• PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007 Dec 15; 67(24):11924-32. ​
• Assessing the significance of chromosonal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA. 2007; 104(50):20007-12. 
• Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):20007-12. 
• Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Dec 06; 450(7171):893-8. 
• Comment on The consensus coding sequences of human breast and colorectal cancers. Science. 2007 Sep 14; 317(5844):1500. 
• LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007 Aug 16; 448(7155):807-10. 
• Cancer: broken genes in solid tumours. Nature. 2007 Aug 02; 448(7153):545-6. 
• The multifunctional protein p54nrb/PSF recruits the exonuclease XRN2 to facilitate pre-mRNA 3' processing and transcription termination. Genes Dev. 2007 Jul 15; 21(14):1779-89. 
• Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell. 2007 Jul; 12(1):81-93. 
• Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007 Jun 15; 129(6):1065-79. 
• Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007 Mar; 11(3):217-27. 
• Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One. 2007 Feb 28; 2(2):e255. 
• The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene. 2007 Jul 26; 26(34):5023-7. 
• Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther. 2007 May; 6(5):661-7. 
• High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51. 
• Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar 01; 25(7):760-6. 
• Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist. 2007 Jan; 12(1):90-8.

2006

• Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 2006 Dec 01; 66(23):11389-98. ​
• Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec; 3(12):e485. 
• Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol. 2006 Nov 01; 24(31):5079-90. 
• Phosphorylation of the menin tumor suppressor protein on serine 543 and serine 583. Mol Cancer Res. 2006 Oct; 4(10):793-801. 
• TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006 Sep 01; 66(17):8337-41. 
• Genomic approaches to lung cancer. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4384s-4391s. 
• Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4403s-4408s. 
• Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4365s-4371s. 
• Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res. 2006 Jul 01; 66(13):6487-91. 
• Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 01; 12(13):3908-14. 
• Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med. 2006 Jul; 12(7):852-5. 
• Epidermal growth factor receptor (EGFR) mutation testing in non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol. 2006 Jun 20; 24(18_suppl):7177. 
• C/EBP alpha mutations in lung cancer. Lung Cancer. 2006 Aug; 53(2):253-4. 
• Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol. 2006 May; 2(5):e41. 
• Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A. 2006 May 16; 103(20):7817-22. 
• Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res. 2006 Mar 15; 66(6):3162-8. 
• A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):751-8.

2005

• Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput Biol. 2005 Nov; 1(6):e65. ​
• The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005 Oct 21; 123(2):207-18. 
• Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov; 2(11):e313. 
• Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 2005 Oct 01; 65(19):8968-74. 
• Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A. 2005 Oct 11; 102(41):14659-64. 
• An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005 Aug 15; 65(16):7096-101. 
• Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005 Jul 07; 436(7047):117-22. 
• Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 2005 Jul 01; 65(13):5561-70. 
• Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol. 2005 May 10; 23(14):3219-26. 
• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr; 7(4):387-97. 
• EGFR gene mutations: a call for global x global views of cancer. J Natl Cancer Inst. 2005 Mar 02; 97(5):326-8. 
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24; 352(8):786-92. 
• Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):565-72. 
• Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A. 2005 Jan 18; 102(3):749-54. 
• The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol. 2005 Jan; 25(2):612-20. 
• Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer. J Clin Oncol. 2005 Jan 01; 23(1):235-7. 
• Lineage addiction in human cancer: lessons from integrated genomics. Cold Spring Harb Symp Quant Biol. 2005; 70:25-34. 
• Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. Cold Spring Harb Symp Quant Biol. 2005; 70:73-81.

2004

• Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004 Dec 15; 64(24):8816-20. ​
• Somatic alterations in the human cancer genome. Cancer Cell. 2004 Nov; 6(5):433-8. 
• Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 2004 Oct 15; 64(20):7241-4. 
• Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res. 2004 Sep; 2(9):489-94. 
• Genomic representations using concatenates of Type IIB restriction endonuclease digestion fragments. Nucleic Acids Res. 2004 Aug 25; 32(15):e121. 
• Assessing prognosis in non-small-cell lung cancer: avenues to a more complete picture? J Clin Oncol. 2004 Aug 15; 22(16):3209-11. 
• Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood. 2004 Sep 15; 104(6):1855-8. 
• Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res. 2004 May 18; 32(9):e71. 
• An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res. 2004 May 01; 64(9):3060-71. 
• EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 04; 304(5676):1497-500. 
• High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene. 2004 Apr 08; 23(15):2716-26. 
• Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell. 2004 Feb 27; 13(4):587-97. 
• Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A. 2004 Feb 17; 101(7):1892-7. 
• Molecular classification and molecular genetics of human lung cancers. Semin Oncol. 2004 Feb; 31(1 Suppl 1):4-19. 
• Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res. 2004 Jan 01; 64(1):64-71.​

2000-2003

• Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res. 2003 Aug 15; 63(16):4781-5. ​
• Human genetic variation and disease. Lancet. 2003 Jul 26; 362(9380):259-60. 
• Pathogen discovery from human tissue by sequence-based computational subtraction. Genomics. 2003 Mar; 81(3):329-35. 
• Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 2002 Dec 01; 62(23):7001-3. 
• Identification of foreign gene sequences by transcript filtering against the human genome. Nat Genet. 2002 Feb; 30(2):141-2. 
• Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001 Nov 20; 98(24):13790-5. 
• Telomerase activation, cellular immortalization and cancer. Ann Med. 2001 Mar; 33(2):123-9. 
• Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nat Biotechnol. 2000 Sep; 18(9):1001-5. 
• Role of telomerase in normal and cancer cells. J Clin Oncol. 2000 Jul; 18(13):2626-34. 
• Recurrent allelic deletions of chromosome arms 15q and 16q in human small cell lung carcinomas. Genes Chromosomes Cancer. 2000 Mar; 27(3):323-31.

Pre-2000

• Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999 Oct; 5(10):1164-70. 
• Telomerase enzyme activation and human cell immortalization. Toxicol Lett. 1998 Dec 28; 102-103:41-5. 
• Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet. 1998 Jun; 19(2):182-6. 
• Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene. 1998 Mar 05; 16(9):1217-22. 
• hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997 Aug 22; 90(4):785-95. 
• The catalytic subunit of yeast telomerase. Proc Natl Acad Sci U S A. 1997 Aug 19; 94(17):9202-7. 
• Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol. 1994 Mar; 14(3):2077-86. 
• Pulmonary embolism: comparison of MR images with radionuclide and angiographic studies. Radiology. 1994 Feb; 190(2):499-508. 
• A family of human cdc2-related protein kinases. EMBO J. 1992 Aug; 11(8):2909-17. 
• Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase. Nature. 1991 Sep 12; 353(6340):174-7. 
• The cyclin-dependent kinase family. Cold Spring Harb Symp Quant Biol. 1991; 56:177-86. 

​All of these articles have Matthew either as primary author or a corresponding author. Papers are sorted by recency.

---

2021-2025

• Mäkinen & Meyerson. Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer. J Clin Invest. 2023 Nov 1;133(21):e174171.
• Hayes & Meyerson. Molecular portraits of lung cancer evolution. Nature. 2023 Apr;616(7957):435-436.​
• Sanders BE, Qiao G, Hirschman J, Meyerson M. Fusobacterium and Colorectal Cancer: Important Association or Random Coincidence? Cancer Res. 2022 Oct 17;82(20):3671-3672.
• ​Aquilanti E, Kageler L, Wen PY, Meyerson M. Telomerase as a therapeutic target in glioblastoma. Neuro Oncol. 2021 Dec 1;23(12):2004-2013.

2016-2020

• Zhang X, Meyerson M. Illuminating the noncoding genome in cancer. Nat Cancer. 2020 Sep;1(9):864-872.
• Bullman S, Meyerson M, Kostic AD. Emerging Concepts and Technologies for the Discovery of Microorganisms Involved in Human Disease. Annu Rev Pathol. 2017 Jan 24;12:217-44. PMID: 27959634
• Bullman S, Zou T, Meyerson M. Mechanistic Insights into Transmissible Cancers of Mammals. Cancer Cell. 2018 Apr 9;33(4):543-44. PMID: 29634941
• Bandopadhayay P, Meyerson M. Landscapes of Childhood Tumours. Nature. 2018;555;316-17. PMID: 29542703
• Zou T, Meyerson M. Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer. Cancer Res. 2019 Mar 15;79(6):1038-1040. PMID: 30877100
• Meyerson M. Bacterial invaders drive CRC progression. Sci Signal. 2020 Aug11;13(644):eabc4218. PMID: 32788340

2011-2015

• Francis J, Lin W, Rozenblatt-Rosen O, Meyerson M. The menin tumor suppressor protein is phosphorylated in response to DNA damage. PLoS One. 2011 Jan 14;6(1):e16119. PMID: 21264250;   PMCID: PMC3021530
• Meyerson M, Pellman D. Cancer genomes evolve by pulverizing single chromosomes. Cell. 2011 Jan 7;144(1):9-10.  PMID: 21215363.
• Chin L, Hahn WC, Getz G, Meyerson M. Making sense of cancer genomic data. Genes Dev. 2011 Mar 15;25(6):534-55.  PMID: 21406553; PMCID: PMC3059829
• Macconaill LE, Van Hummelen P, Meyerson M, Hahn WC. Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov. 2011 Sep 1;1(4):297.  PMID: 21935500;   PMCID: PMC3175123
• Jänne PA, Meyerson M. ROS1 Rearrangements in Lung Cancer: A New Genomic Subset of Lung Adenocarcinoma. J Clin Oncol. 2012 Mar 10;30(8):878-9. Epub 2012 Jan 3.  PMID: 22215755
• Liao RG, Watanabe H, Meyerson M, Hammerman PS. Targeted therapy for squamous cell lung cancer. Lung Cancer Manag. 2012 Dec;1(4):293-300. PMID:23956794,   PMCID: PMC3744181
• Watanabe H, Meyerson M. Hopping between Differentiation States in Lung Adenocarcinoma. Cancer Cell. 2013 Jun 10;23(6):707-9. PMID: 23763994; PMCID: PMC3748274.
• Kostic AD, Chun E, Meyerson M, Garrett WS. Microbes and inflammation in colorectal cancer. Cancer Immunol Res. 2013 Sep;1(3):150-7. PMID: 24777677
• Chmielecki J, Meyerson M. DNA Sequencing of Cancer: What Have We Learned? Annu Rev Med. 2014;6563-79. PMID: 24274178.
• Watanabe H, Brooks AN, Meyerson M. Breaking down RET breakpoints in lung adenocarcinoma. J Thorac Oncol. 2014 May;9(5):590-2. PMID: 24722148; PMCID: PMC4036692

2006-2010

• Thomas RK, Weir B, Meyerson M. Genomic approaches to lung cancer. Clin Cancer Res. 2006;12:4384s-91s. PMID: 16857815
• Meyerson M. Cancer: broken genes in solid tumours. Nature. 2007 Aug 2;448(7153):545-6. PMID: 17671492
• MacConaill L, Meyerson M. Adding pathogens by genomic subtraction. Nat Genet. 2008 Apr;40(4):380-2. PMID: 18368124
• Wistuba II, Meyerson M. Chromosomal deletions and progression of premalignant lesions: less is more. Cancer Prev Res (Phila). 2008 Nov;1(6):404-8. PMID: 19138986
• Bass AJ, Meyerson M. Genome-wide association study in esophageal squamous cell carcinoma. Gastroenterology. 2009 Nov;137(5):1573-6. PMID: 19789091
• Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010 Oct;11(10):685-96. Review.  PMID: 20847746

2000-2005

• Meyerson M. Role of telomerase in normal and cancer cells. J Clin Oncol. 2000;18(13):2626-34. PMID: 10893296
• Hahn WC, Meyerson M. Telomerase activation, cellular immortalization and cancer. Ann Med. 2001;33(2):123-9. PMID: 11327115
• Meyerson M. Human genetic variation and disease. Lancet. 2003 Jul 26;362(9380):259-60. PMID: 12892951
• Meyerson M, Franklin WA, Kelley MJ. Molecular classification and molecular genetics of human lung cancers. Semin Oncol. 2004;31(1Suppl 1):4-19. PMID: 14981576
• Dubinett SM, Elashoff D, Meyerson M. Assessing prognosis in non small-cell lung cancer avenues to a more complete picture? J Clin Oncol. 2004;22(16):3209-11. PMID: 15249586
• Weir B, Zhao X, Meyerson M. Somatic alterations in the human cancer genome. Cancer Cell. 2004. Nov;6(5):433-8. PMID: 15542426
• Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clinical Oncol. 2005. May 10;23(14):3219-26. PMID: 15886309
• Sellers WR, Meyerson M. EGFR gene mutations: a call for global x global views of cancer. J Natl Cancer Inst. 2005;97(5):326-8. PMID: 15741561

Pre-2000

• ​Meyerson M. Telomerase enzyme activation and human cell immortalization. Toxicol Lett. 1998;102-103:41-5. PMID: 10022230

Walter DM, Cho K, Sivakumar S, Lee IT-H, Dohlman AB, Shurberg E, et al. U2AF1 mutations rescue deleterious exon skipping induced by KRAS mutations. bioRxiv [Preprint]. 2025 Mar 25:2025.03.25.644128. doi: https://doi.org/10.1101/2025.03.21.644128.

Sadagopan A, Meyerson M. p53 protein abundance is a therapeutic window across TP53 mutant cancers and is targetable with proximity inducing small molecules. bioRxiv [Preprint]. 2024 July 27. doi: https://doi.org/10.1101/2024.07.27.605429.